Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 844 Therapeutics > Exam 5 - Dyslipidemia Chaudhry > Flashcards

Exam 5 - Dyslipidemia Chaudhry Flashcards

1
Q

what values are included in a FLP? (4 of them)

A

TC
TG
HDL-C
LDL-C (using Friedewald Eq)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the Friedewald equation and what is it used for?

A

LDL = TC - HDL -TG/5

Used to estimate LDL from FLP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

lifestyle management: how much sodium intake should pts get daily?

A

< 1500 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what does DASH diet stand for?

A

dietary approach to stop HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is Olestra? (from internet)

A

-A fat substitute made from sucrose and vegetable oil.
-Used to reduce intake of saturated fats and cholesterol
-Not available in USA anymore

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

which is not a soluble fiber used to decrease LDL?

a. oat bran
b. pectins or gums
c. Olestra
d. Psyllium products

A

c. Olestra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

lifestyle changes: ___-___ grams daily of sterols can dec LDL 6-15%

A

2-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how much physical activity should patients get?

A

40 mins 3-4 times a week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

if overweight, ___% weight loss is recommended

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the two omega-3 fatty acid prescription products?

A

Lovaza
Vascepa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the only triglyceride risk-based nonstatin therapy FDA approved for ASCVD risk reduction?

A

icosapent ethyl (IPE)

(brand name Vascepa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

statins, BARs, ezetimibe, PCSK9 mAB, Inclisiran, and bempedoic acid mainly decrease serum

a. LDL
b. HDL
c. TG

A

a. LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

fibrates, omega 3 FA, and niacin mainly decrease serum

a. LDL
b. HDL
c. TG

A

c. TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which two statins are preferred in renal impairment?

A

fluvastatin, atorvastatin

(no dosing adjustments needed)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

four low intensity statins:

simvastatin ___ mg
pravastatin ___-___ mg
lovastatin ___ mg
fluvastatin ___-___ mg

A

simvastatin 10 mg
pravastatin 10-20 mg
lovastatin 20 mg
fluvastatin 20-40 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

two high intensity statins:

atorvastatin ___-___ mg
rosuvastatin ___-___ mg

A

atorvastatin 40-80 mg
rosuvastatin 20-40 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what are the TWO hydrophilic statins?

a. fluvastatin
b. pitavastatin
c. pravastatin
d. lovastatin
e. simvastatin
f. atorvastatin
g. rosuvastatin

A

c. pravastatin
g. rosuvastatin

(the others are lipophilic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

statin contraindications (4; slide 46)

A

-acute liver disease
-unexplained, persistent elevations of serum transaminases
-pregnancy
-breastfeeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

if a pt is on statins and experiences muscle injury, what changes can we make to their therapy? (3)

A

-d/c statin to see if pain resolves
-switch to lower risk statin (hydrophilic)
-consider alternative dosing strategies (every other day, once weekly, etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

simvastatin considerations: do not exceed ___ mg daily with verapamil or diltiazem

A

10 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

simvastatin considerations: do not exceed ___ mg daily with amiodarone, amlodipine, or ranolazine

A

20 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

3 bile acid resins (BAR) drugs

A

-cholestyramine
-colestipol
-colesevelam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

one DISADVANTAGE of bile acid resins is that they may inc

a. LDL
b. TC
c. TG

A

c. TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

for BARs, other meds should be taken ___ hour(s) before or ___ hour(s) after

A

1 hour before; 4 hours after

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

cholestyramine contraindication

A

complete biliary obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

colesevelam contraindications (3)

A

-history of bowel obstruction
-history of hypertriglyceridemia-induced pancreatitis
-serum TG > 500 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

we are worried about pancreatitis when TG > ___ mg/dL

A

500 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what causes Niacin flushing?

A

caused by interaction with skin causing prostaglandins to be released and dilation of vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

administer ASA 325 mg ___ minutes before taking Niacin for flusing and/or itching

A

30 min

30
Q

Niacin contraindications (4)

A

-active hepatic disease
-significant or unexplained persistent liver transaminase elevations
-active peptic ulcer
-arterial hemorrhage

31
Q

what drug is a cholesterol absorption inhibitor?

A

ezetimibe (Zetia)

32
Q

what drug is ezetimibe + simvastatin?

A

Vytorin

33
Q

ezetimibe adverse effects (3)

A

-fatigue
-diarrhea
-GI upset

34
Q

ezetimibe contraindications (3 of them)

A

-concomitant use with a statin and active hepatic disease or unexplained persistent serum transaminase elevations
-pregnancy (when used w/ statin)
-breastfeeding (when used w/statin)

35
Q

gemfibrozil and fenofibrate are in which drug class?

A

fibrates

36
Q

fibrates contraindications (3)

A

-history of gallbladder disease
-ESRD or dialysis
-persistent liver disease

37
Q

what are the three PCSK9 mAb drugs we talked about?

A

alirocumab (Praluent)
evolocumab (Repatha)
inclisiran (Leqvio)

38
Q

Indication for PCSK9 monoclonal antibodies, inclisiran (Leqvio), bempedoic acid

A

adjunct to diet and statin to reduce LDL in familial heterozygous hypercholesterolemia or ASCVD

39
Q

MOA for Praluent and Repatha

A

-inhibits binding of PCSK9 to LDL receptors and upregulate the recycling of LDL receptors, causing dec in LDL-C (43-64%)

(PCSK9 protein normally breaks down LDL receptors so we have less of them. An inhibitor will stop the protein from working so we have more LDL receptors on liver and less cholesterol in blood)

40
Q

which is not a side effect of fibrates?

a. GI disturbances
b. rash
c. myalgia
d. influenza
e. dizziness

A

d. influenza

41
Q

inclisiran (Leqvio) MOA

A

-long-acting synthetic small interfering ribonucleic acid (siRNA) that inhibits translation of PCSK9 protein thus inhibiting PCSK9 production, prolonging activity of LDL receptors

(basically siRNA inhibits PCSK9 production)

42
Q

how is Leqvio dosed?

A

get initial dose, another at 3 months, then after every 6 months

(it’s an injection)

43
Q

bempedoic acid may increase blood _____ _____ levels and lead to the development of _____

A

uric acid; gout

44
Q

true or false: bempedoic acid should be avoided concomitant use with simvastatin > 20 mg and pravastatin > 40 mg

A

true (due to myopathy)

45
Q

bempedoic acid is a prodrug activated in liver by what enzyme?

A

ACSVL1 (very-long-chain acyl-CoA synthetase-1)

46
Q

what enzyme does bempedoic acid inhibit?

A

ACL (ATP-citrate lyase)

47
Q

true or false: activated bempedoic acid is present in skeletal muscle

A

false

48
Q

active ingredient in red yeast rice

A

lovastatin

49
Q

boxed warning for lomitapide (Juxtapid)

A

risk of hepatotoxicity

50
Q

what protein does lopitamide inhibit?

A

MTTP (microsomal triglyceride transfer protein)

(prevents assembly of apoB containing lipoproteins in enterocytes and hepatocytes…there is more to the mechanism; slide 79)

51
Q

lomitapide (Juxtapid) and evinacumab (Evkeeza) are used for what disease state?

A

homozygous familial hypercholesterolemia (HoFH)

52
Q

what does evinacumab inhibit?

A

ANGPTL3 (angiopoietin-like protein 3)

(rest of mech is on slide 81)

53
Q

if LDL-C is 190 or greater, what intensity statin would we use?

A

high intensity

54
Q

TG over what # is reasonable to initiate a statin?

A

> 500

55
Q

therapy in severe hypertriglyceridemia: adults 40-75 with severe hypertriglyceridemia and especially those with TG of 1000 or more

a. favors initiation or intensification of statin therapy to reduce ASCVD risk
b. initiate statin treatment
c. initiate statin treatment + fibrate OR omega3

A

c. initiate statin treatment + fibrate OR omega3

56
Q

what are the two go-to pharmacological therapies to dec risk of acute pancreatitis?

A

fibrates or omega 3 FA’s

57
Q

evinacumab (Evkeeza) is an additional med that can be used in adjunct with other meds to lower LDL-C in pts with

a. heterozygous familial hypercholesterolemia
b. homozygous familial hypercholesterolemia

A

b. homozygous familial hypercholesterolemia

58
Q

for primary prevention of pt with LDL-C of 190 or more, what strength statin should be used?

A

high intensity statin

59
Q

for primary prevention of 40-75 year old pt with diabetes, what strength statin should be used?

A

moderate-high intensity statin

60
Q

guidelines for < 20 year old pt with LDL-C 160+ and familial hypercholesterolemia

A

initiate statin

61
Q

what age range do we start having to assess 10-year ASCVD risk?

A

40-75

62
Q

risk discussion for low risk (< 5%) 10-year ASCVD risk pts

A

emphasize lifestyle to reduce risk factors

63
Q

risk discussion for borderline risk (5 - < 7.5%) 10-year ASCVD risk pts

A

if risk enhancers present then discuss moderate-intensity statin

64
Q

risk discussion for intermed risk (7.5 - < 20%) 10-year ASCVD risk pts

A

if risk estimate + risk enhancers favor statin, initiate moderate-intensity statin to reduce LDL-C by 30-49%

65
Q

risk discussion for high risk (20% or more) 10-year ASCVD risk pts

A

initiate statin to reduce LDL-C by 50% or more

66
Q

if risk discussion is uncertain, what test can we consider to determine initiation of statin?

A

coronary artery calcium (CAC) test

(CT of chest to measure calcium buildup)

67
Q

true or false: if coronary artery calcium (CAC) test comes up with CAC = 1-99, this favors statin therapy, especially age 55+

A

true

68
Q

what treatment does a CAC of 100 or more indicate?

A

initiation of at least moderate-intensity statin

69
Q

fasting TG > 150 following at least 4-12 weeks of lifestyle intervention, a stable dose of a max tolerated statin, and a secondary cause evaluation

a. persistent hypertriglyceridemia
b. moderate hypertriglyceridemia
c. severe hypertriglyceridemia

A

a. persistent hypertriglyceridemia

70
Q

TG of 150-499

a. persistent hypertriglyceridemia
b. moderate hypertriglyceridemia
c. severe hypertriglyceridemia

A

b. moderate hypertryglyceridemia

71
Q

TG > ____ mg/dL is considered severe hypertriglyceridemia

A

> 500 mg/dL

PHRM 844 Therapeutics (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions